









Markets
/
Stocks
/
nasdaq-ycbd
/

cbdMD Inc

YCBD

0.658USD

-0.062-8.62%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

5.86MMarket Cap

LossP/E TTM



cbdMD Inc

0.658

-0.062-8.62%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

101 / 175

Overall Ranking

337 / 4720

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Buy

Current Rating

2.000

Target Price

+177.93%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

cbdMD, Inc. is a cannabidiol (CBD) company. The Company has a comprehensive line of United States produced, THC-free CBD products, including NSF Certified for Sport products, as well as its new Full Spectrum products. The Company's flagship brands include cbdMD and Paw CBD, as well as its functional mushroom brand ATRx Labs. Its cbdMD brand includes high-grade, premium CBD products including CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD sleep aids and CBD drink products including its Herbal Oasis Social Tonic and an array of Farm Act compliant Delta 9 products. Its Paw CBD brand of pet products includes veterinarian-formulated products including tinctures, chews, topicals products in varying strengths, and its ATRx brand of natural functional mushroom support. Its cbdMD, Paw CBD and ATRx products are distributed through its e-commerce websites, third party e-commerce sites, select distributors and marketing partners as well as a variety of brick-and-mortar retailers.

Growing

The company is in a growing phase, with the latest annual income totaling USD 19.48M.

Overvalued

The company’s latest PE is -0.44, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 1.71M shares, increasing 47.57% quarter-over-quarter.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of -0.27.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 7.66, which is lower than the Pharmaceuticals industry's average of 7.84. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 4.61M, representing a year-over-year decrease of 10.96%, while its net profit experienced a year-over-year decrease of 127.23%.

Score

Industry at a Glance

Previous score

7.66

Change



Financials

6.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.50

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.52

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.26

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -0.48, which is -0.77% below the recent high of -0.48 and -232.33% above the recent low of -1.59.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 101/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.00, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for cbdMD Inc is 2.00, with a high of 2.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 1 analysts

Buy

Current Rating

2.000

Target Price

+177.93%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

cbdMD Inc

YCBD

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 1.42, which is lower than the Pharmaceuticals industry's average of 6.84. Sideways: Currently, the stock price is trading between the resistance level at 0.81 and the support level at 0.62, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

1.42

Change

-0.04

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.008

Neutral

RSI(14)

40.491

Neutral

STOCH(KDJ)(9,3,3)

22.768

Sell

ATR(14)

0.046

Low Volatility

CCI(14)

-130.695

Sell

Williams %R

100.000

Oversold

TRIX(12,20)

-0.596

Sell

StochRSI(14)

15.192

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.691

Sell

MA10

0.694

Sell

MA20

0.708

Sell

MA50

0.808

Sell

MA100

0.899

Sell

MA200

2.034

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Crc Investment Fund LP

1.23M

Porter (Jeffrey H)

73.26K

Citadel Advisors LLC

15.79K

Coffman (Raymond Scott)

48.46K

Lambeth (Marianne)

46.70K

GSA Capital Partners LLP

3.97K

Virtu Americas LLC

8.88K

+55.68%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 2.98, which is lower than the Pharmaceuticals industry's average of 4.07. The company's beta value is 2.30. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.